Glaukos (NYSE:GKOS) shares plummeted today despite fourth-quarter results that beat the consensus forecast. GKOS shares dropped down -27.4% at $44.60 per share in early-morning trading today. The San Clemente, Calif.–based ophthalmic medical technology and pharmaceutical company posted profits of $36.6 million, or 84¢ per share, on sales of $65.8 million for the three months ended Dec. […]
Procept Biorobotics taps industry veteran as new CEO
Procept BioRobotics recently announced that Reza Zadno, former CEO of ophthalmology tech company Avedro, has taken over the corner office at Procept. Zadno has more than three decades of leadership in the medical device industry, with a track record of successfully leading young companies to acquisitions. The latest was Avedro, which Glaukos (NYSE:GKOS) acquired for an […]
Glaukos completes Avedro buy
Glaukos (NYSE:GKOS) today said it completed its acquisition of Glaukos for an undisclosed amount. Avedro develops single-use drug formulations that are designed to strengthen corneal tissues and stop the progression of degenerative corneal ectatic disease keratoconus. Get the full story on our sister site, Drug Delivery Business.
Glaukos slides on Q3 profit drop
Glaukos (NYSE:GKOS) shares dropped today on third-quarter earnings that topped the consensus forecast despite sliding profits. The San Clemente, Calif.-based ophthalmic medical technology and pharmaceutical company posted losses of -$13.5 million, or -37¢ per share, on sales of $58.5 million for the three months ended Sept. 30, for a large bottom-line slide on sales growth of […]
These 10 medtech companies care a lot about research
These 10 medical device companies spent the largest portion of their budgets on research and development. Here’s a look at what they produced. Each year, Medical Design & Outsourcing compiles a list of the top 100 medical device companies across the globe and ranks the companies based on annual revenue for the most recent fiscal year. We […]
On mixed Q2 results, Glaukos announces Avedro buy
Glaukos (NYSE:GKOS) posted its second-quarter financial results this week and reported that it plans to acquire Avedro in an effort to build out its corneal health franchise. Avedro develops single-use drug formulations designed to strengthen corneal tissue and stop the progression of a degenerative corneal ectatic disease known as keratoconus. According to the Mass.-based company, the total U.S. […]
Glaukos licenses eye drug-delivery tech from Intratus
Glaukos (NYSE:GKOS) said today that it inked a licensing deal with Intratus for that company’s transdermal drug delivery platform for treating eye conditions. San Diego-based Intratus developed cream-based drug formulations that are applied to the outer eyelid to treat conditions such as dry eye disease, glaucoma, allergy, blepharitis and conjunctivitis. The deal gives San Clemente, Calif.-based […]
The 17 most innovative medical devices of 2019
The Galien Foundation recently announced nominees for most innovative medical devices for its 13th Annual Prix Galien USA Awards. The foundation awards the Prix Galien Award annually to examples of outstanding biomedical and technology product achievements that are designed to improve human condition. Nominees need to be FDA approved for market within the last five […]
Glaukos closes $3m Dose Medical buy
Glaukos (NYSE:GKOS) said yesterday that closed the nearly $3 million plus milestones to acquire former subsidiary Dose Medical and its drug-delivery technology for treating retinal diseases. Sam Clemente, Calif.-based Glaukos spun Dose out as a standalone company in 2010, but paid $26 million in July 2015 for Dose Medical’s glaucoma assets. Get the full story at our sister site, […]
Glaukos posts Street-topping Q1 earnings
Glaukos (NYSE:GKOS) yesterday posted first quarter 2019 earnings that topped both loss per share and sales expectations on Wall Street. The San Clemente, Calif.-based company posted losses of $1.3 million, or 4¢ per share, on sales of approximately $54 million for the three months ended March 31, seeing losses shrink 50.5% while sales grew 34.6% when […]
Glaukos, Santen ink U.S. MicroShunt distro deal
Glaukos (NYSE:GKOS) said last Friday that it inked a multi-year distribution deal with Santen Pharmaceutical (OTC:SNPHY) to market its MicroShunt device, intended to reduce intraocular pressure in patients with primary open-angle glaucoma (POAG), in the U.S. Through the deal, San Clemente, Calif.-based Glaukos will become the exclusive U.S. distributor of the MicroShunt, which is being studied in […]
- 1
- 2
- 3
- …
- 6
- Next Page »
MassDevice Network
@MassDevice
LinkedIn
YouTube